

業績（論文）

【2024】

- 1) Nakagawa C., Ota R., Hirata A., Yokoyama S., Uno T., Hosomi K., Reasons and predictors of treatment change in rheumatoid arthritis patients treated with biological and targeted synthetic disease-modifying antirheumatic drugs: a single-center retrospective observational study, *Biol Pharm Bull*, in press.
- 2) Hayashi T., Miyamoto T., Iwane S., Fujitani M., Uchitani K., Koizumi Y., Hirata A., Kinoshita H., Kawabata A., Opposing impact of hormone therapy-related hypertension/diabetes and preexisting statins on castration resistant progression of nonmetastatic prostate cancer: a multicenter, *Sci Rep*, in press.
- 3) Yoshikawa T., Okamoto H., Takeuchi K., Hirata A., Otake H., Nagai N., Evaluation of starch granules based on hydroxypropylcellulose as a substitute for excipient lactose, *Journal of Pharmaceutical Health Care and Sciences*, 2024, **10**, 31.
- 4) Ota R., Hirata A., Hata T., Nishihara M., Neo M., Katsumata T., Incidence of serious infections in the working-age Japanese adult population with rheumatoid arthritis treated with tumor necrosis factor- α inhibitors and interleukin-6 inhibitors: A nationwide retrospective cohort study, *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 2024, **44**, 570-580.
- 5) Kataoka N., Hata T., Hosomi K., Hirata A., Fujiwara S., Goto E., Nishihara M., Ohmichi M., Neo M., Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study. *J Chemother*, 2024, **2**, 1-7.
- 6) Iwane S., Nemoto W., Miyamoto T., Hayashi T., Tanaka M., Uchitani K., Muranaka T., Fujitani M., Koizumi Y., Hirata A., Tsubota M., Sekiguchi F., Tan-No K., Kawabata A., Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy, *Sci Rep*, 2024, **14**, 1039.

【2023】

- 1) Tanaka Y., Ota R., Hirata A., Yokoyama S., Nakagawa C., Uno T., Hosomi K., Effect of baseline urinary glucose levels on the relationship between sodium-glucose cotransporter 2 inhibitors and serum uric acid in Japanese patients with type 2 diabetes mellitus, *Pharmazie*, 2023, **78**, 238-244.
- 2) Kataoka N., Hata T., Hosomi K., Hirata A., Goto E., Nishihara M., Inamoto T., Azuma H., Neo M., Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study., *International journal of*

clinical pharmacology and therapeutics, 2023, **61**, 386-393.

- 3) Ota R., Hata T., Hirata A., Hamada T., Nishihara M., Neo M., Katsumata T., Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study, *Br J Clin Pharmacol*, 2023, **89**, 2168-2178.

【2022】

- 1) Hata T., Hirata A., Ota R., Hosohata K., Nishihara M., Neo M., Katsumata T., Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database, *Ther Clin Risk Manag*, 2022, **18**, 843-853.
- 2) Yamashiro K., Jouta M., Hosomi K., Yokoyama S., Ozaki Y., Hirata A., Ogata F., Nakamura T., Tanei S., Kawasaki N., Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database, *Sci Rep*, 2022, **12**, 17652.
- 3) Murakami A., Noto K., Ota R., Hirata A., Analysis of Factors Affecting Proteinuria Onset Timing in Patients Treated with Bevacizumab, *Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan*, 2022, **142**, 641-649.

【2021】

- 1) Yamashiro K., Hirata A., Ota R., Ogata F., Nakamura T., Kawasaki N., Time-dependent changes in serum magnesium levels in patients receiving cetuximab with low baseline serum sodium levels, *Pharmazie*, 2021, **76**, 625-628.
- 2) Yamashiro K., Hirata A., Ota R., Ogata F., Nakamura T., Kawasaki N., Relationship between renal dysfunction and change in serum electrolyte levels in patients administered with liposomal amphotericin B, *Fundamental Toxicological Sciences*, 2021, **8**, 147-155. .
- 3) Hirata A., Ota R., Hata T., Hamada T., Nishihara M., Uchiyama K., Katsumata T., Prescribing Trends of Biologic Disease-Modifying Anti-rheumatic Drugs Using a Claims Database from 6 Million People in Japan, *Clin Drug Investig*, 2021, **41**, 967-974.
- 4) Hayashi T., Miyamoto T., Nagai N., Kawabata A., Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance, *Sci Rep*, 2021, **11**, 17157.
- 5) Ota R., Hirata A., Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet, *J Chemother*, 2021, **33**, 539-546.
- 6) Yamashiro K., Hirata A., Ota R., Ogata F., Nakamura T., Kawasaki N., Relationship between serum potassium magnesium and calcium in patients receiving cetuximab therapy, *BPB Reports*, 2021, **4**, 22-26.

【2020】

- 1) Ota R., Hirata A., Noto K., Yokoyama S., Hosomi K., Takada M., Matsuoka H., Relationship between serum calcium and creatinine in hematopoietic stem cell transplantation patients treated with foscarnet, *International journal of clinical pharmacology and therapeutics*, 2020, **58**, 274-281.
- 2) Okamoto H., Yoshikawa T., Takeuchi K., Deguchi S., Hatakenaka Y., Matsuoka H., Kawabata A., Nagai N., A Combination of Cryopreservation and Kneading Maintains the Usability of Mohs Paste, *Chem Pharm Bull*, 2020, **68**, 516-519.
- 3) Hayashi T., Kawaguchi H., Eifuku T., Matsuoka H., Kawabata A., Nagai N., Changes in Percutaneous Absorption of Fentanyl Patches in Rats Treated with a Sebum-Like Secretion, *Chem Pharm Bull*, 2020, **68**, 879-884.

【2019】

- 1) 林 友典, 高科 結衣, 川口 陽奈子, 永福 紡, 松岡 寛, 川畑 篤史, 長井 紀章, フラント型拡散セルを用いた市販フェンタニルテープの経皮吸収性の評価: 温熱条件下における薬物放出性と皮膚透過性の測定, *医療薬学*, 2019, **45**, 416-422.
- 2) 畑 武生, 平田 敦士, 濱田 武, 能登 啓介, 太田 涼介, 西原 雅美, 松岡 寛, 勝間田 敬弘, 向精神薬の過量服薬による急性毒性のリスク評価, *日本病院薬剤師会雑誌*, 2019, **55**, 1216-1222.
- 3) 太田 涼介, 平田 敦士, 畑 武生, 能登 啓介, 福井 愛子, 西原 雅美, 勝間田 敬弘, 松岡 寛, 有害事象自発報告データベース(JADER)を用いたニューキノロン系抗菌薬の横紋筋融解症に関する解析, *日本病院薬剤師会雑誌*, 2019, **55**, 619-624.
- 4) Ota R., Hirata A., Noto K., Yokoyama S., Hosomi K., Takada M., Matsuoka H., Relationship between the blood concentrations of tacrolimus and voriconazole in hematopoietic stem cell transplant recipients, *International journal of clinical pharmacology and therapeutics*, 2019, **57**, 561-566.
- 5) Hirata A., Noto K., Ota R., Yokoyama S., Hosomi K., Takada M., Matsuoka H., Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin, *International journal of clinical pharmacology and therapeutics*, 2019, **57**, 135-143.

【2018】

- 1) 能登 啓介, 平田 敦士, 畑 武生, 太田 涼介, 福井 愛子, 林 友典, 西原 雅美, 勝間田 敬弘, 松岡 寛, 国内の有害事象自発報告データベース (JADER) を用いた抗アレルギー薬の鎮静等の有害事象に関する解析, *日本病院薬剤師会雑誌*, 2018, **54**, 63-68.

※日本病院薬剤師会『学術奨励賞』受賞

【2017】

- 1) 緒方 文彦, 林 友典, 平田 敦士, 能登 啓介, 松岡 寛, 川崎 直人, 簡易懸濁法適応時における NaCl の影響およびチューブ通過性に関する基礎的研究, *臨床環境医学*, 2017, **26**, 45-54.
- 2) Fujiwara Y., Fukuda S., Tsujie M., Kitani K., Inoue K., Hayashi T., Ishikawa H., Yukawa M., Inoue M., Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S-1 adjuvant chemotherapy, *Oncol Lett*, 2017, **14**, 1621-1627.

【～2016】

- 1) 平田 敦士, 能登 啓介, 林 友典, 岡本 広世, 太田 涼介, 西浦 早織, 松岡 寛, 医薬品情報検索システムの構築および他職種間での質問内容の実態調査, *日本病院薬剤師会雑誌*, 2015, **51**, 541-544.
- 2) 長井 紀章, 緒方 文彦, 塚本 あゆみ, 林 友典, 西浦 早織, 松岡 寛, 小竹 武, 川崎 直人, 伊藤 吉将, デキストリン併用投与がクレメジン®細粒経管投与時の低回収率およびチューブ詰まりに与える影響, *薬局薬学*, 2014, **6**, 22-27.
- 3) 長井 紀章, 緒方 文彦, 林 友典, 西浦 早織, 松岡 寛, 川崎 直人, 伊藤 吉将, カリメート®散経管投与時の低回収率およびチューブ詰まりに対するデキストリンの保護効果, *医療薬学*, 2013, **39**, 33-38.
- 4) 平田 敦士, 松岡 寛, 落合 孝充, 中尾 治香, 西浦 早織, 立花 貞信, 疑義照会情報共有システムの構築および紙媒体を利用した照会内容のフィードバック化の有用性, *日本病院薬剤師会雑誌*, 2012, **48**, 67-71.
- 5) 西浦 早織, 中村 暢彦, 平井 三保子, 紙谷 公彦, 籠本 基成, 石津 雅弘, 高齢者における FOLFOX 療法の有害事象発現に対する後ろ向き調査, *日本病院薬剤師会雑誌*, 2010, **46**, 905-908.
- 6) 緒方 文彦, 川崎 直人, 林 友典, 西浦 早織, 松岡 寛, 立花 貞信, 掛樋 一晃, 簡易懸濁法適用時におけるベシル酸アムロジピンを主成分とする製剤（先発品および後発品）の溶出量, *医療薬学*, 2010, **36**, 874-879.
- 7) Yamazoe Y., Tsubaki M., Matsuoka H., Satou T., Itoh T., Kusunoki T., Kidera Y., Tanimori Y., Shoji K., Nakamura H., Ogaki M., Nishiura S., Nishida S., Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells, *Cell Biol Int*, 2009, **33**, 1087-1094.
- 8) Matsuoka H., Tsubaki M., Yamazoe Y., Ogaki M., Satou T., Itoh T., Kusunoki T., Nishida S., Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways, *Exp Cell Res*, 2009, **315**,

2022-2032.

- 9) Taga A., Kita S., Nishiura K., Hayashi T., Kinoshita M., Sato A., Suzuki K., Kodama S., Kakehi K., Analysis of an antibody pharmaceutical, tocilizumab, by capillary electrophoresis using a carboxylated capillary, *J Sep Sci*, 2008, **31**, 853-858.
- 10) Fujiwara K., Tsubaki M., Yamazoe Y., Nishiura S., Kawaguchi T., Ogaki M., Nishinobo M., Shimamoto K., Moriyama K., Nishida S., Fluvastatin induces apoptosis on human tongue carcinoma cell line HSC-3, *Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan*, 2008, **128**, 153-158.
- 11) Tsubaki M., Matsuoka H., Yamamoto C., Kato C., Ogaki M., Satou T., Itoh T., Kusunoki T., Tanimori Y., Nishida S., The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2, *Clin Exp Metastasis*, 2007, **24**, 431-438.
- 12) Tsubaki M., Kato C., Manno M., Ogaki M., Satou T., Itoh T., Kusunoki T., Tanimori Y., Fujiwara K., Matsuoka H., Nishida S., Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways, *Mol Cell Biochem*, 2007, **304**, 53-60.
- 13) Nishida S., Matsuoka H., Tsubaki M., Tanimori Y., Yanae M., Fujii Y., Iwaki M., Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK, *Mol Cell Biochem*, 2005, **269**, 109-114.
- 14) Kamoda S., Nomura C., Kinoshita M., Nishiura S., Ishikawa R., Kakehi K., Kawasaki N., Hayakawa T., Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis, *J Chromatogr A*, 2004, **1050**, 211-216.